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Abstract 
We describe here the design, synthesis and evaluation of in vivo local anaesthetic and 
antiarrhythmic activities of a series of N-alkylproline anilides. Most of the compounds 
demonstrated surface anaesthetic activity higher than that of lidocaine, ropivacaine and 
bupivacaine. We established that the local anaesthetic activity was sensitive to structural variations 
in the substitution pattern at the aromatic ring and the type of alkyl group at the proline nitrogen 
atom. Some of the prepared N-alkylproline anilides possessed significant antiarrhythmic activity 












   
1. Introduction 
Local anaesthetics are drugs clinically used to produce reversible loss of sensation in a 
confined area of the body. Nowadays local anaesthetics play an important role in clinical 
management of acute, chronic and cancer pain [1-3]. Moreover local anaesthetics represent one of 
the most frequently used in daily medical practice groups of drugs [4]. At the same time, application 
of available anaesthetics was reported [5,6]
 
 to induce some severe adverse effects including life 
threatening conditions, signifying therefore importance of development of new safer local 
anaesthetic agents. 
The first clinically available amide based local anaesthetic, lidocaine (Fig. 1), was 
synthesized by Swedish chemist Nils Lofgren in 1943 [7]. This drug was characterized by fast onset 
of action, strong and relatively long lasting effect, exceeded by these parameters ester based 
anaesthetics of that time. Lidocaine opened a new avenue for development of local anaesthetics and 
its structural features, such as tertiary amino group and arylamide moiety connected with one 
carbon atom, became a classical pattern for most of the modern local anaesthetics (Fig. 1). In the 
process of development of new more potent local anesthetics, N,N-dialkyl derivatives of glycine 
evolved to N-alkyl substituted homoprolines and prolines. Thus Ekenstam introduced homoproline-
based mepivacaine, bupivacaine and ropivacaine (Fig. 1) in clinical practice as very potent local 
anaesthetics [8-10]. At the same time effective anaesthetics, derivatives of proline, namely 
cyclomecaine and pyromecaine were developed [11]. However, therapeutic application of these 
drugs is limited due to their substantial general toxicity [12] and associated side effects[13,14]. 
Furthermore, a discovery of antiarrhythmic properties of lidocaine in the event of ventricular 
fibrillation during cardiac catheterisation [15] initiated a number of studies devoted to search of new 
local anaesthetics and antiarrhythmics among arylamides of α-amino acids [16,17]. It has been 
established that both the anaesthetic and antiarrhythmic effects realise via the same mechanism 
involving mainly blocking voltage-gated sodium [18], calcium [19] and to some extent potassium 
[20] channels thus causing membrane stabilisation and therefore preventing initiation of the action 
potentials. Since that time, further development of anaesthetic and antiarrhythmic drugs has been 
often parallel. 
Although the main trend in modern drug design and development inclines towards search for 
agents highly selective against one particular target, it appears that all clinically available 
anaesthetics are scarcely selective to any specific type and subtype of the ion channels. They all 
have been discovered on the basis of in vitro and in vivo tests assessing changes in the neurone 
functions. This can be attributed to incomplete knowledge of actual role of each type and subtypes 
of the ion channels in the activity. Therefore it seems practical to conduct search for new 
anaesthetic and antiarrhythmic agents using assays based on the desirable therapeutic outcome.  
In this study we focus on the compounds with the N-alkyl proline core, which seems to be 
preferable over N-alkyl homoproline due to lower toxicity of the derivatives based on this scaffold 
[9]. Herein we report synthesis and biological activity of N-alkyl derivatives of proline anilides, 
which can be considered as structural analogues of cyclomecaine, one of the most potent modern 
local anaesthetics [11,21]. Effects of two types of structural variations on the anaesthetic and 
antiarrhythmic activity were explored: (1) substituents on the phenyl ring of the anilide fragments 
and (2) type of alkyl group at the nitrogen atom of the proline fragment. The activity and toxicity of 
the compounds were compared with structurally related cyclomecaine and widely used anaesthetics 
lidocaine, bupivacaine and ropivacaine. 
 
2. Chemistry 
The synthesis of N-alkyl derivatives of proline anilides (4) for pharmacological 
investigations was performed as outlined in Scheme 1. The design of the synthetic pathway allowed 
exploration of substitution at the two critical for biological activity positions of the final compounds 
4. The bromination of 5-chloropentanoic acid (1) in α-position using molecular bromine in the 
presence of phosphorus trichloride afforded 2-bromo-5-chloropentanoic acid, which was converted 
into corresponding acid chloride 2. Then arylamides of 2-bromo-5-chloropentanoic acid (3) were 
prepared by treatment of 2 with various anilines in mild conditions. The treatment of 3 with primary 
alkylamines under heating in toluene resulted in the intramolecular cyclization with formation of 
arylamides of N-alkylprolines, which were further converted into the corresponding hydrochloric 
salts 4. ortho-Toluidide of N-methylproline (4a) has been previously reported and its physico-
chemical and spectral characteristics are in agreement with the literature values [22]. 
In DMSO solution, most of the anilides of N-alkylproline hydrochlorides (4) appeared as a 
mixture of two diastereomers due to the second stereogenic center introduced by protonation of the 
proline nitrogen. The diastereomer ratio depends on the type of substituents and conditions of the 
NMR experiments. Thus, only one cis-form was observed for 4a and 4m. Despite of evident 
stabilization of the trans-form via intramolecular hydrogen bonding, this form was always minor 
and its content in the mixture never exceeded 20%. 
 
3. Results and discussion 
All synthesised compounds (4a-4p) were evaluated in vivo for their local anaesthetic and 
antiarrhythmic activities. Initial screening of the compounds for local anaesthetic activity was 
performed using a commonly used surface anaesthesia model on rabbit cornea [23]. Further 
elaboration in the rat infiltration anaesthesia model [24] was carried out for the most promising 
compounds. 
 
3.1. Surface local anaesthetic activity 
Surface anaesthetic activity of the compounds was evaluated in white New Zealand rabbits 
using the corneal reflex test [23]. This test was used as the initial screening model due to its high 
sensitivity and relative simplicity. Most of the prepared compounds were found to possess surface 
anaesthetic activity in this test at 1% concentration (Table 1).  
The results of structure-activity relationship analysis revealed some important features 
responsible for the anaesthetic effect of the compounds. Classical substitution pattern in the 
aromatic ring of local anaesthetics of the arylamide class (Fig. 1) typically include at least one 
methyl group in the ortho-position (e.g. prilocaine), more often two (e.g. lidocaine, bupivacaine and 
ropivacaine) and sometimes the third one in para-position (e.g. trimecaine, cyclomecaine and 
pyromecaine). We also found that in our series of compounds, methyl substituent was optimal for 
the activity. Even slight increase in the length of the alkyl chain from methyl (compound 4c) to 
ethyl (4g) group dramatically reduced surface local anaesthetic activity. We believe that this fact 
was linked with a clearly observable local irritative effect of 4g. Similarly to the previously reported 
data [9, 22], we found that increase in the number of methyl groups translated into increase of 
potency and duration of local anaesthetic effect. Interestingly, 2,4- and 2,6-xylidides (4d and 4e) 
demonstrated almost no difference in the activity. Changing the ortho-methyl to trifluoromethyl 
group or a halogen significantly decreased depth and duration of the surface anaesthesia. 
Introduction of a second halogen in para-position resulted in complete loss of anaesthetic effect.  
Type of the N-alkyl substituent at the pyrrolidine ring was found to be critical for the surface 
local anaesthetic activity. The N-methyl and ethyl substituted 4a and 4b possessed no anaesthetic 
activity in this assay. It appeared that the alkyl substituent should contain more than two carbon 
atoms. Extension of the chain from n-butyl (4c) to n-pentyl (4k) and further to n-hexyl (4l) in N-
alkyl proline ortho-toluidides led to some increase of the Regnier index and significantly 
lengthened the anaesthetic activity. Making the alkyl chain even longer seemed to be unnecessary 
due to local irritative effect and poor aqueous solubility, previously reported for the similar 
structures with longer N-alkyl chain in the pyrrolidine ring [22]. The cyclohexyl substituted 
derivatives 4n and 4o demonstrated practically the same level and duration of anaesthesia as their 
corresponding n-butyl analogues 4c, e. Interestingly, despite recent reports [25-27] on high in vitro 
sodium channel blocking potential of 2,6-xylidine analogue of 4m - NeP1 (Fig. 1), introduction of a 
N-benzyl moiety into the pyrrolidine ring of ortho-toluidine derivative appeared to abolish 
anaesthetic activity. All the above observations were found to be very close to those earlier reported 
[22] for the analogous mesidides and seemed to be general for this class of local anaesthetics. 
 
3.2. Infiltration local anaesthetic activity 
The most active in the surface local anaesthesia test compounds (4d, 4l and 4o) were 
subjected to the infiltration anaesthesia assay in rats [24].
 
The anaesthetic activity was assessed by 
the onset, depth and duration of the muscle contraction blockade. The contractions were stimulated 
by electrical current (0.3 ms, 50 Hz, 0.36-14.0 V). The depth of anaesthesia was expressed as a 
percentage increase of the initial value of stimulation threshold. An increase of the stimulation 
threshold value more than 2 times from initial values was considered as a complete (100%) 
anaesthesia. To gain further understanding of a role of the second methyl group in the arylamino 
moiety, ortho-toluidide derivative 4c was also tested in the assay and its effect was compared with 
that of 2,6-xylidide substituted analogue 4d.  
All compounds and reference drugs demonstrated fast onset of action blocking muscle 
contractions within 1-2 min after administration. The duration of anaesthesia caused by the tested 
compounds 4c, 4d, 4l and 4o ranged between 35.0±4.1 and 126.3±24.3 min. Similarly to the 
reference drugs bupivacaine and ropivacaine, compound 4c (Fig. 2A) completely blocked the 
muscle contraction at the first minute. However duration of the complete anaesthesia for 4c was 
shorter (12.5±2.9 min) compare to bupivacaine and ropivacaine, which completely prevent the 
stimulated muscle contraction for 102.5±37.9 and 58.8±17.5 min, respectively. The depth of 
anaesthesia for compound 4c decreased sharply and the threshold values return to the normal in 
35.0±4.1 min after application.  
Compound 4d, 2,6-xylidine analogue of 4c, with the higher surface anaesthetic activity 
demonstrated only 90% increase of the threshold values in the infiltration anaesthesia assay (Fig. 
2B). However duration of the anaesthetic action for 4d was longer with the maximal block lasted 
for 20.0±13.5 min followed by slow recovery. No significant difference with the initial threshold 
values was observed in 71.3±19.3 min after administration of 4d.  
Compounds 4l and 4o were practically equipotent in terms of depth and duration of the 
surface local anaesthesia, but these compounds demonstrated distinct profiles in the infiltration 
anaesthesia assay (Figs. 2C and 2D). Both compounds possessed long-acting local anaesthetic 
activity exceeding the effect duration of ropivacaine (80.0±15.8 min). Thus, 4l was effective for 
115.0±12.2 min, while 4o induced even longer (126.3±24.3 min) infiltration anaesthesia. 
Bupivacaine was found to be active for 155.0±11.5 min with 102.5±37.9 min of the complete 
anaesthesia.  
In general, 4d, 4l and 4o were more active than lidocaine, ropivacaine and bupivacaine in 
inducing surface anaesthesia, though duration of their effects was shorter than that of bupivacaine. 
At the same time, these compounds (4d, 4l and 4o) were less potent in the infiltration anaesthesia 
assay than bupivacaine and seemed to be less suitable for this type of therapeutic applications. 
Significantly lower toxicity of 4o compare to the reference drugs (vide infra) was one of the main 
advantages making this compound a suitable candidate for further investigations.  
 
3.3. Antiarrhythmic activity 
Antiarrhythmic activity of the synthesized compounds was estimated by their ability to 
prevent mortality in the event of calcium chloride induced arrhythmia in mice [28]. To exclude 
contribution of the intrinsic toxicity of the compounds to the mortality, acute toxicity (LD50) [29] of 
the compounds in mice was estimated prior to their testing in the antiarrhythmic assay. Effective 
dose (ED50) was determined only when it was less than ½ of LD50.  
In general, the compounds active in the anaesthetic tests also were found to be effective in 
the antiarrhythmic assay. However, unlike the local anaesthetic activity, antiarrhythmic properties 
of the compounds tolerated various types of ortho-subtituents at the phenyl ring if other positions 
remained intact. Moreover, ortho-methyl substituted compounds were more toxic than their 
corresponding analogues. Introduction of the second methyl group in position 4 (para) decreased 
toxicity of the compounds (4e and 4o), while the same group in position 6 (ortho) significantly 
increased toxicity (4d). It seems that for cyclomecaine with the 2,4,6-trimethyl substitution, methyl 
groups in positions 4 and 6 cancelled effects of each other in terms of toxicity, but appeared to be 
very beneficial for the antiarrhythmic effect.  
Similarly to the local anaesthetic activity, four or more carbons in the chain of N-alkyl 
substituent at the pyrrolidine ring were required for the compounds to possess antiarrhythmic 
properties. N-Methyl and ethyl substituted 4a and 4b were inactive at the tested doses. However, in 
contrast to the local anaesthetic activity, increasing the alkyl group size did not correlate with 
improvement of antiarrhythmic activity. N-Benzyl substituted 4m, which was inactive in the surface 
local anaesthesia assay, appeared to be effective in the prevention of calcium chloride induced 
arrhythmia in mice.  
In general, six compounds (4f, 4h, 4k, 4l, 4o and 4p) exhibited better than the reference 
drugs antiarrhythmic/toxicity profile. The combination of N-cyclohexyl substitution in pyrrolidine 
ring and 2,4-xylidide moiety (compound 4o) were found to be optimal, balancing high potency and 
relatively low toxicity. Antiarrhythmic index of this compound (7.3) significantly exceeded the 
same parameter of the reference drugs. Another even less toxic candidate for further development 
as an antiarrhythmic agent could be 4p with the antiarrhythmic index of 6.9. 
 
4. Conclusion 
N-Alkyl derivatives of proline anilides (4) were synthesized and proved to be a prospective 
group for the search of new local anaesthetic and antiarrhythmic agents. Among the tested 
compounds, N-cyclohexyl substituted proline 2,4-xylidide (4o) was the most promising compound 
in terms of surface anaesthetic and antiarrhythmic actions possessing at the same time significantly 
lower toxicity than the reference drugs. Toluidide 4l demonstrated similar potency in local 
anaesthetic and antiarrhythmic assays together with lower than the reference drug toxicity. 2,6-
Xylidide 4d induced high level of surface anaesthesia, but was one of the most toxic in the series. 
ortho-Chloroanilide 4p exhibited relatively low anaesthetic activity, but could be interesting for 
further development as an antiarrhythmic agent with low toxicity. 
  
5. Experimental  
 
5.1. Chemistry 
Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus in 
open capillaries. The 
1
H NMR spectra were recorded on a Mercury-300BB spectrometer (300 MHz) 
in CDCl3 and DMSO-d6 using TMS as an internal standard.  
 
5.1.1. 2-Bromo-5-chloropentanoic acid (2) 
5-Chloropentanoic acid (1, 52.2 g, 0.382 mol) and dry bromine (76.8 g, 0.480 mol) in the 
presence of phosphorus trichloride (4 ml, 45.8 mmol) were heated on water bath at 80°C for 20 h, 
then the heating was continued at 100°C for 2 h. After cooling to ambient temperature, the reaction 
mixture was treated with 250 ml of water. The organic layer was extracted with benzene (3 times). 
After drying over anhydrous MgSO4, the solvent was evaporated under reduced pressure to give 
75.1 g of 2-bromo-5-chloropentanoic acid (2) as oil. 
1
H NMR (CDCl3), δ (ppm): 1.72-2.40 (m, 4H), 
3.53 (t, 2Н, J = 5.6 Hz), 4.23 (dd, 1Н, J = 7.4, 6.5 Hz), 10.46 (br. s, 1H). Anal. Calc. for 
C5H8BrClO2: C, 27.87; H, 3.74. Found: C, 27.74; H, 3.51. 
 
5.1.2. 2-Bromo-5-chloropentanoic acid chloride (3) 
2-Bromo-5-chloropentanoic acid (2) was mixed with thionyl chloride (0.870 mol, 103.6 g) 
and heated under reflux in water bath for 1.5 h. The excess of thionyl chloride was removed under 
reduced pressure affording 72.9 g of 2-bromo-5-chloropentanoic acid chloride (3). 
1
H NMR 
(CDCl3), δ (ppm): 1.74-2.42 (m, 4H), 3.55 (t, 2Н, J = 6.1 Hz), 4.51 (dd, 1Н, J = 7.4, 5.6 Hz). Anal. 
Calc. for C5H7BrCl2O: C, 25.67; H, 3.02. Found: C, 25.46; H, 2.94. 
 
5.1.3. Hydrochlorides of o-toluidide of N-methylproline (4a) and o-toluidide of N-ethylproline (4b) 
Solution of 2-bromo-5-chloropentanoic acid chloride (2, 23.4 g,100 mmol) in chloroform 
(40 ml) was added dropwise at 0-5 °C during 45 min to the mixture of o-toluidine (10.72 g, 100 
mmol) and triethylamine (10.1 g, 100 mmol) in chloroform (50 ml) and the reaction mixture was 
heated under reflux for 1 h. After cooling, the mixture was treated with 3% hydrochloric acid (100 
ml) and the organic layer was collected, washed with water to neutral pH and evaporated. The 
residue was recrystallized from hexane to give o-toluidide of 2-bromo-5-chloropentanoic acid (3), 
which was dissolved in toluene (30 mmol in 100 ml), mixed with potassium iodide (0.2 g, 1.2 
mmol) and treated with dry gaseous methylamine or ethylamine via bubbling for 6 h. The 
precipitate was filtered off and the filtrate was treated with saturated K2CO3 aqueous solution (100 
ml). The organic layer was collected, dried over anhydrous MgSO4 and evaporated under reduced 
pressure. The residue was dissolved in dry diethyl ether and treated with gaseous HCl. The 
precipitated product was filtered, washed with acetone and recrystallized from acetonitrile (for 4a) 
or acetone/diethyl ether (for 4b) providing corresponding o-toluidides of N-alkylproline 
hydrochlorides (4a and 4b).  
 
5.1.3.1. o-Toluidide of N-methylproline (4a)  
Yield 74%; mp 219-221 °C (MeCN); 
1
H NMR (DMSO-d6), δ (ppm): 1.82-2.12 (m, 2H), 
2.22 (s, 3Н), 2.55-2.70 (m, 2Н), 2.85 (s, 3Н), 3.42-3.68 (m, 2Н), 4.43 (dt, 1Н, J = 7.8, 8.4 Hz), 
6.98-7.38 (m, 4H, Ar), 9.85 (br. s, 1H), 10.59 (s, 1Н). Anal. Calc. for C13H19ClN2O: C, 61.29; H, 
7.52; N, 11.00. Found: C, 61.13; H, 7.41; N, 10.91. 
 
5.1.3.2. o-Toluidide of N-ethylproline (4b) 
Yield 52%; mp 188 °C (acetone/Et2O); 
1
H NMR (DMSO-d6), δ (ppm): 1.24 (t, 3Н, J = 6.9 
Hz), 1.89-2.18 (m, 2H), 2.23 (s, 3H), 2.60-2.71 (m, 2Н), 3.19-3.32 (m, 2H), 3.60-3.72 (m, 2Н), 4.48 
(dt, 1Н, J = 8.1, 7.5 Hz), 4.70* (m, 1H), 7.12-7.39 (m, 4H, Ar), 9.60 (br. s,1H), 10.28* (s, 1H), 
10.59 (s, 1Н), 11.99* (br. s, 1H); * - signals of the minor trans-diastereomer. Anal. Calc. for 
C14H21ClN2O: C, 62.56; H, 7.88; N, 10.42. Found: C, 62.39; H, 7.72; N, 10.37. 
 
5.1.4. Hydrochlorides of anilides of N-alkylproline (4c-4p) 
Solution of 2-bromo-5-chloropentanoic acid chloride (2, 23.4 g,100 mmol) in chloroform 
(40 ml) was added dropwise at 0-5 °C during 45 min to the mixture of substituted aniline (100 
mmol) and triethylamine (10.1 g, 100 mmol) in chloroform (50 ml) and the reaction mixture was 
heated under reflux for 1 h. After cooling, the mixture was treated with 3% hydrochloric acid (100 
ml) and the organic layer was collected, washed with water to neutral pH and evaporated. The 
residue was recrystallized from hexane to give anilides of 2-bromo-5-chloropentanoic acid (3), 
which were dissolved in toluene (30 mmol in 100 ml), mixed with triethylamine (6.1 g , 60 mmol) 
and primary alkylamine (45 mmol). Then potassium iodide (0.2 g, 1.2 mmol) was added and the 
reaction mixture was heated under reflux for 25 h. After cooling, the precipitate was filtered off and 
the filtrate was treated with saturated K2CO3 aqueous solution (100 ml). The organic layer was 
collected, dried over anhydrous MgSO4 and evaporated under reduced pressure. The residue was 
dissolved in dry diethyl ether and treated with gaseous HCl. The precipitated product was filtered, 
washed with acetone and recrystallized from appropriate solvent providing anilides of N-
alkylproline hydrochlorides (4).  
 
5.1.4.1. o-Toluidide of N-butylproline (4c) 
Yield 55%; mp 202-204 °C (1,4-dioxane/toluene, 1:1); 
1
H NMR (DMSO-d6), δ (ppm) 0.85 
(t, 3Н, J = 6.5 Hz), 1.22-1.38 (m, 2H), 1.48-1.80 (m, 2H), 1.92-2.10 (m, 2H), 2.16 (s, 3H), 2.56-
2.64 (m, 2Н), 3.12-3.34 (m, 2H), 3.50-3.75 (m, 2Н), 4.36-4.80 (m, 1Н), 6.95-7.34 (m, 4H, Ar), 9.50 
(br. s, 1H), 10.32* (s, 1H), 10.70 (s, 1Н), 11.98* (br. s, 1H); * - signals of the minor trans-
diastereomer. Anal. Calc. for C16H25ClN2O: C, 64.74; H, 8.49; N, 9.44. Found: C, 64.60; H, 8.36; 
N, 9.38. 
 
5.1.4.2. 1,6-Xylidide of N-butylproline (4d) 
Yield 64%; mp 244-246 °C (i-PrOH); 
1
H NMR (DMSO-d6), δ (ppm) 0.90 (t, 3Н, J = 6.9 
Hz), 1.22-1.38 (m, 2H), 1.52-1.78 (m, 2H), 1.91-2.10 (m, 2H), 2.15 (s, 6H), 2.42-2.58 (m, 2Н), 
3.12-3.28 (m, 2H), 3.51-3.68 (m, 2Н), 4.38-4.78 (m, 1Н), 6.90-7.15 (m, 3H, Ar), 9.45 (br. s, 1H), 
10.35* (br. s, 1H), 10.70 (s, 1Н), 11.95* (br. s, 1H); * - signals of the minor trans-diastereomer. 
Anal. Calc. for C17H27ClN2O: C, 65.68; H, 8.75; N, 9.01. Found: C, 65.66; H, 8.68; N, 8.94. 
 
5.1.4.3. 1,4-Xylidide of N-butylproline (4e) 
Yield 58%; mp 182-184 °C (1,4-dioxane/toluene, 1:1); 
1
H NMR (DMSO-d6), δ (ppm) 0.88 
(t, 3Н, J = 6.5 Hz), 1.25-1.40 (m, 2H), 1.50-1.75 (m, 2H), 1.85-2.10 (m, 2H), 2.15 (s, 3H), 2.25 (s, 
3H), 2.50-2.70 (m, 2Н), 3.09-3.28 (m, 2H), 3.48-3.71 (m, 2Н), 4.35-4.65 (m, 1Н), 6.89 (d, 1H, J = 
7.4 Hz), 6.94 (s, 1H), 7.11 (d, 1H, J = 7.4 Hz), 9.50 (br. s, 1H), 10.05* (s, 1H), 10.65 (s, 1Н), 
11.97* (br. s, 1H); * - signals of the minor trans-diastereomer. Anal. Calc. for C17H27ClN2O: C, 
65.68; H, 8.75; N, 9.01. Found: C, 65.58; H, 8.64; N, 8.90.  
 
5.1.4.4. o-Trifluoromethylanilide of N-butylproline (4f) 
Yield 62%; mp 210-212 °C (MeCN/toluene, 1:1); 
1
H NMR (DMSO-d6), δ (ppm) 0.89 (t, 
3Н, J = 6.5 Hz), 1.21-1.40 (m, 2H), 1.40-1.70 (m, 2H), 1.88-2.20 (m, 2H), 2.54-2.71 (m, 2Н), 3.16-
3.34 (m, 2H), 3.55-3.75 (m, 2Н), 4.28-4.70 (m, 1Н), 7.30-7.80 (m, 4H, Ar), 9.55 (br. s, 1H), 10.56* 
(s, 1H), 10,90 (s, 1Н), 12.10* (br. s, 1H); * - signals of the minor trans-diastereomer. Anal. Calc. 
for C16H22ClF3N2O: C, 54.78; H, 6.32; N, 7.99. Found: C, 54.69; H, 6.27; N, 7.91.  
 
5.1.4.5. o-Ethylanilide of N-butylproline (4g) 
Yield 56%; mp 182-184 °C (acetone); 
1
H NMR (DMSO-d6), δ (ppm) 0.88 (t, 3Н, J = 6.5 
Hz), 1.10 (t, 3H, J = 7.4 Hz), 1.25-1.30 (m, 2H), 1.40-1.70 (m, 2H), 1.85-2.20 (m, 2H), 2.45-2.75 
(m, 4H), 3.10-3.29 (m, 2H), 3.50-3.70 (m, 2Н), 4.35-4.75 (m, 1Н), 7.05-7.30 (m, 4H, Ar), 9.50 (br. 
s, 1H), 10.23* (s, 1H), 10.63 (s, 1Н), 12.05* (br. s, 1H); * - signals of the minor trans-diastereomer. 
C17H27ClN2O: C, 65.68; H, 8.75; N, 9.01. Found: C, 65.61; H, 8.69; N, 8.95. 
 
5.1.4.6. o-Iodoanilide of N-butylproline (4h) 
Yield 66%; mp 203-205 °C (acetone/EtOH, 9:1); 
1
H NMR (DMSO-d6), δ (ppm) 0.89 (t, 3H, 
J = 7.0 Hz), 1.16-1.33 (m, 2H), 1.52-1.68 (m, 2H), 1.93-2.17 (m, 2H), 2.42-2.68 (m, 2Н), 3.15-3.30 
(m, 2H), 3.54-3.76 (m, 2Н), 4.28-4.61 (m, 1Н), 6.99 (t, 1H, J = 7.4 Hz), 7.18-7.45 (m, 2H), 7.83 (d, 
1H, J = 7.4 Hz), 9.51 (br. s, 1H), 10.43* (s, 1H), 10.71 (s, 1Н), 11.98* (br. s, 1H); * - signals of the 
minor trans-diastereomer. Anal. Calc. for C15H22ClIN2O: C, 44.08; H, 5.43; N, 6.85. Found: C, 
43.97; H, 5.38; N, 6.78.  
 
5.1.4.7. 2,4-Dichloroanilide of N-butylproline (4i) 
Yield 55%; mp 197-199 °C (acetone/Et2O); 
1
H NMR (DMSO-d6), δ (ppm) 0.94 (t, 3Н, J = 
7.3 Hz), 1.30-1.43 (m, 2H), 1.56-1.61 (m, 2H), 1.92-2.13 (m, 2H), 2.67-2.74 (m, 2Н), 3.15-3.30 (m, 
2H), 3.65-3.75 (m, 2Н), 4.58 (dt, 1H, J = 7.2, 9.0 Hz), 4.77* (dd, 1H, J = 7.5, 4.5 Hz), 7.37-7.67 (m, 
3H, Ar), 9.73 (br. s, 1H), 10.56* (s, 1H), 11.05 (s, 1Н), 12.36* (br. s, 1H); * - signals of the minor 
trans-diastereomer. Anal. Calc. for C15H21Cl3N2O: C, 51.23; H, 6.02; N, 7.97. Found: C, 51.20; H, 
5.97; N, 7.91.  
 
5.1.4.8. 2,4-Dibromoanilide of N-butylproline (4j) 
Yield 66%; mp 192-194 °C (1,4-dioxane); 
1
H NMR (DMSO-d6), δ (ppm) 0.88 (t, 3Н, J = 
6.8 Hz), 1.22-1.43 (m, 2H), 1.52-1.68 (m, 2H), 1.89-2.21 (m, 2H), 2.58-2.77 (m, 2Н), 3.12-3.27 (m, 
2H), 3.48-3.77 (m, 2H), 4.32-4.71 (m, 1Н), 7.38 (d, 1H, J = 7.4 Hz), 7.58 (d, 1H, J = 7.4 Hz), 7.71 
(s, 1H), 9.60 (br. s, 1H), 10.60* (s, 1H), 10.90 (s, 1Н), 12.05* (br. s, 1H); * - signals of the minor 
trans-diastereomer. Anal. Calc. for C15H21ClBr2N2O: C, 40.89; H, 4.80; N, 6.36. Found: C, 40.76; 
H, 4.71; N, 6.27.  
 
5.1.4.9. o-Toluidide of N-pentylproline (4k) 
Yield 56%; mp 201-203 °C (1,4-dioxane); 
1
H NMR (DMSO-d6), δ (ppm) 0.91 (t, 3Н, J = 
6.8 Hz), 1.26-1.40 (m, 4H), 1.60-1.73 (m, 2H), 1.92-2.19 (m, 2H), 2.26 (s, 3H), 2.62-2.76 (m, 2Н), 
3.12-3.30 (m, 2H), 3.64-3.75 (m, 2Н), 4.62 (dt, 1Н, J = 7.8, 8.4 Hz), 7.10-7.25 (m, 3H, Ar) 7.35 
(dd, 1H, J = 7.2, 1.8 Hz), 9.64 (br. s, 1H), 10.25* (s, 1H), 10.84 (s, 1Н), 12.25* (br. s, 1H); * - 
signals of the minor trans-diastereomer. Anal. Calc. for C17H27ClN2O: C, 65.68; H, 8.75; N, 9.01. 
Found: C, 65.57; H, 8.66; N, 8.93. 
 
5.1.4.10. o-Toluidide of N-hexylproline (4l) 
Yield 56%; mp 148-150 °C (ethyl acetate); 
1
H NMR (DMSO-d6), δ (ppm) 0.89 (t, 3Н, J = 
6.6 Hz), 1.25-1.40 (m, 6H), 1.58-1.72 (m, 2H), 1.92-2.20 (m, 2H), 2.25 (s, 3H), 2.60-2.75 (m, 2Н), 
3.10-3.32 (m, 2H), 3.64-3.74 (m, 2Н), 4.49 (dt, 1Н, J = 8.1, 7.5 Hz), 4.67-4.73* (m, 1H), 7.10-7.39 
(m, 4H, Ar), 9.57 (br. s, 1H), 10.11* (s, 1H), 10.51 (s, 1Н), 12.20* (br. s, 1H); * - signals of the 
minor trans-diastereomer. Anal. Calc. for C18H29ClN2O: C, 66.54; H, 9.00; N, 8.62. Found: C, 
66.41; H, 8.90; N, 8.54. 
 
5.1.4.11. o-Toluidide of N-benzylproline (4m) 
Yield 75%; mp 213-215 °C (1,4-dioxane/toluene, 1:1); 
1
H NMR (DMSO-d6), δ (ppm) 1.88-
2.10 (m, 2H), 2.06 (s, 3Н), 2.60-2.73 (m, 2Н), 3.55-3.70 (m, 2Н), 4.47 (dd, 2H, J = 6.9, 13.5 Hz), 
4.55 (dt, 1Н, J = 6.9, 8.1 Hz), 7.01-7.22 (m, 4H, Ar), 7.41-7.60 (m, 5H, Ar), 9,85 (br. s, 1H), 10.36 
(s, 1Н). Anal. Calc. for C19H23ClN2O: C, 68.97; H, 7.01; N, 8.47. Found: C, 68.86; H, 6.91; N, 8.35. 
 
5.1.4.12. o-Toluidide of N-cyclohexylproline (4n) 
Yield 56%; mp 244-246 °C (1,4-dioxane/toluene, 1:1); 
1
H NMR (DMSO-d6), δ (ppm) 1.18-
1.40 (m, 6Н), 1.84-1.93 (m, 2Н), 1.97-2.14 (m, 4Н), 2.24 (s, 3H), 2.54-2.60 (m, 2Н), 3.25-3.40 (m, 
2Н), 3.55-3.69 (m, 1Н), 4.75 (dt, 1H, J = 7.5, 9.0 Hz), 7.13-7.39 (m, 4H), 9.36 (br. s, 1H), 10.30* 
(s, 1H), 10.68 (s, 1Н), 11.93* (br. s, 1H); * - signals of the minor trans-diastereomer. Anal. Calc. 
for C18H27ClN2O: C, 66.96; H, 8.43; N, 8.68. Found: C, 66.81; H, 8.32; N, 8.55. 
 
5.1.4.13. 1,4-Xylidide of N-cyclohexylproline (4o) 
Yield 37%; mp 248-250 °C (MeCN); 
1
H NMR (DMSO-d6), δ (ppm) 1.18-1.40 (m, 6Н), 
1.85-1.92 (m, 2Н), 1.98-2.14 (m, 4Н), 2.17 (s, 3H), 2.23 (s, 3H), 2.46-2.54 (m, 2Н), 3.14-3.36 (m, 
2Н), 3.42-3.63 (m, 1Н), 4.56-4.78 (m, 1Н), 6.92 (d, 1H, J = 8.4 Hz), 6.97 (s, 1H), 7.13 (d, 1H, J = 
8.4 Hz), 9.20 (br. s, 1H), 10.11* (s, 1H), 10.50 (s, 1Н), 11.80* (br. s, 1H); * - signals of the minor 
trans-diastereomer. Anal. Calc. for C18H27ClN2O: C, 67.74; H, 8.68; N, 8.32. Found: C, 67.68; H, 
8.52; N, 8.27. 
 
5.1.4.14. o-Chloroanilide of N-cyclohexylproline (4p) 
Yield 38%; mp 222-224 °C (MeCN); 
1
H NMR (DMSO-d6), δ (ppm) 1.18-1.42 (m, 6Н), 
1.86-1.95 (m, 2Н), 2.00-2.16 (m, 4Н), 2.24 (s, 3H), 2.54-2.60 (m, 2Н), 3.25-3.40 (m, 2Н), 3.55-3.69 
(m, 1Н), 4.75 (dt, 1H, J = 7.5, 9.0 Hz), 7.13-7.39 (m, 4H), 9.36 (br. s, 1H), 10.30* (s, 1H), 10.68 (s, 
1Н), 11.93* (br. s, 1H); * - signals of the minor trans-diastereomer. Anal. Calc. for C17H24Cl2N2O: 
C, 59.48; H, 7.05; N, 8.16. Found: C, 59.36; H, 6.94; N, 8.07. 
 
5.2. Biological activity  
 
5.2.1. Surface local anaesthetic activity assay 
Surface anaesthetic activity was evaluated in white New Zealand rabbits using modified 
Regnier corneal reflex test [23]. Briefly, aqueous solutions (1%, 0.25 ml) of compounds 4a-p or 
reference drugs were instilled into the conjunctival sac of the animals during 30 sec. The tactile 
stimulations of the rabbit cornea (up to 100 in a series) with the pointer were applied in 8 min after 
the treatment and then in the define intervals (10, 12, 15 min and then every 5 min). The summation 
of numbers of the stimulations required to cause the corneal reflex during 1 h (13 series) provided 
the Regnier index. The duration of the anaesthesia was estimated as a time required for complete 
restoration of the corneal reflex. Each compound was tested in 6 animals.  
 
5.2.2. Infiltration local anaesthetic activity assay 
Infiltration anaesthetic activity of the compounds was evaluated in Wistar rats using 
modification of the reported method [24]. Briefly, after identification of sensitive areas on the 
shaved skin of lumbar region of the rat back and determination of the electrical stimulation 
(rectangular pulses, 0.36 to14.0 V, 0.3 ms, 50 Hz) threshold initiating the surface muscle 
contraction, the animals were injected with 0.5% solution of the tested compounds or reference 
drugs in saline (0.2 ml, intradermally and 0.2 ml, subcutaneously). The electrical stimulation 
required to cause the muscle contraction was measured in 3 and 5 min after the injection; then the 
measurements were continued with 5 min intervals until recovery to the initial threshold value. The 
depth of anaesthesia was expressed as a percentage change in the stimulation threshold compare to 
the initial value. Increase of the stimulation threshold value more than 2 times was considered as 
100% anaesthesia. Each compound was evaluated on 6 rats. 
 
5.2.3. Antiarrhythmic activity assay 
Antiarrhythmic activity was evaluated in Swiss albino mice using calcium chloride-induced 
arrhythmia model [28]. The compounds and reference drugs were administrated i.v. in the doses up 
to ½ LD50. After 15 min, cardiac arrhythmia was induced by i.v. injection of calcium chloride 
solution (3%, 280 mg/kg). The antiarrhythmic efficacy of the compounds was expressed as mean 
effective doses (ED50) preventing arrhythmia associated mortality. 
 
5.2.4. Toxicity evaluation 
The acute toxicity of the compounds was determined using albino Swiss mice of both sexes 
with body weight 18-22 g. The aqueous solutions of the compounds were injected via the tail vein 
in increasing doses. After the treatment, animals were observed for possible mortality cases and 
behavioural changes for 72 h. LD50 values were estimated according to reported method [29].  
 
Acknowledgments 
We acknowledge financial support of Russian Ministry of Education and Science. 
 
References  
[1] A. Borgeat, J. Aguirre, Curr. Opin. Anaesthesiol. 23 (2010) 466-471. 
[2] J. Guindon, J.-S. Walczak, P. Beaulieu, Drugs 67 (2007) 2121-2133. 
[3] L. B. Santamaria, D. Schifilliti, D. La Torre, V. Fodale, Surg. Oncol. 19 (2010) 63-81. 
[4] A. S. Gaffen, D. A. Haas, J. Can. Dent. Assoc. 75 (2009) 649. 
[5] R. Fuzier, M. Lapeyre-Mestre, K. Samii, J.-L. Montastruc, Drug Saf. 32 (2009) 345-356. 
[6] R. Fuzier, M. Lapeyre-Mestre, Expert Opin. Drug Saf. 9 (2010) 759-769. 
[7] M. H. Holmdahl, Acta Anaesthesiol. Scand. Suppl 113 (1998) 8-12. 
[8] K. G. Dhuner, B. Egner, B. A. F. Ekenstam, O. Oljelund, L. R. Ulfendahl, Br. J. Anaesth. 28 
(1956) 503-506. 
[9] B. T. Af Ekenstam, B. Egner, G. Pettersson, Acta Chem. Scand. 11 (1957) 1183-1190. 
[10] B. T. Af Ekenstam, C. Bovin, WO Patent 8500599 (1985); Chem. Abstr. 103 (1985) 160393.  
[11] N. T. Pryanishnikova, A. S. Lebedeva, A. M. Likhosherstov, G. I. Gurevich, M. A. Izraélit, I. 
V. Fedina, M. F. Runova, M. I. Shmar'yan, A. P. Skoldinov, Pharm. Chem. J. 5 (1971) 7-9. 
[12] L. E. Mather, Expert Opin. Drug Metab. Toxicol. 6 (2010) 1313-1332. 
[13] G. A. Albright, Anesthesiology 51 (1979) 285-287. 
[14] G. Di Gregorio, J. M. Neal, R. W. Rosenquist, G. L. Weinberg, Reg. Anesth. Pain. Med. 35 
(2010) 181-187. 
[15] J. L. Southworth, V. A. McKusick, E. C. Pierce, 2
nd
, F. L. Rawson, Jr. J. Am. Med. Assoc. 143 
(1950) 717-721. 
[16] F. E. Goda, A. A. M. Abdel-Aziz, H. A. Ghoneim, Bioorg. Med. Chem. 13 (2005) 3175-3183. 
[17] C. Zalaru, F. Dumitrascu, C. Draghici, E. Cristea, I. Tarcomnicu, ARKIVOC (ii) (2008) 308-
314. 
[18] A. Nardi, N. Damann, T. Hertrampf, A. Kless, ChemMedChem 7 (2012) 1712-1740. 
[19] X. Guo, N. A. Castle, D. M. Chernoff, G. R. Strichartz, Ann. N. Y. Acad. Sci. 625 (1991) 181-
199. 
[20] C. H. Kindler, M. Paul, H. Zou, C. Liu, B. D. Winegar, A. T. Gray, C. S. Yost, J. Pharmacol. 
Exp. Ther. 306 (2003) 84-92. 
[21] A. K. Grenader, M. S. Okon, A. K. Filippov, V. I. Porotikov, Pharm. Chem. J. 20 (1986) 154-
157. 
[22] A. M. Likhosherstov, N. T. Pryanishnikova, A. S. Lebedeva, A. P. Skoldinov, Pharm. Chem. J. 
4 (1970), 492-495. 
[23] J. Regnier, Bull. Sci. Pharm. 30 (1923) 580-586.  
[24] E. Bulbring, I. Wajda, J. Pharmacol. 85 (1945) 78-84.  
[25] A. De Luca, S. Talon, M. De Bellis, J.-F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. 
Franchini, V. Tortorella, D. C. Camerino, Mol. Pharmacol. 64 (2003) 932-945. 
[26] C. Ghelardini, J. F. Desaphy, M. Muraglia, F. Corbo, R. Matucci, A. Dipalma, C. Bertucci, M. 
Pistolozzi, M. Nesi, M. Norcini, C. Franchini, D. C. Camerino, Neuroscience 169 (2010) 863-873. 
[27] A. Carrieri, M. Muraglia, F. Corbo, C. Pacifico, Eur. J. Med. Chem. 44 (2009) 1477-1485. 
[28] V. V. Gorbunova, N. P. Gorbunov, Farmakol. Toksikol. 46(3) (1983) 48-50.  







Figure 1. Local anaesthetics – arylamides of amino acids  
 
Figure 2. Infiltration anaesthesia activity of selected compounds: 4c (A), 4d (B), 4l (C) and 4o (D). 
Data are mean values ± SEM 
 
Scheme 1. Synthesis of N-alkyl derivatives of proline anilides (4a–4p) 
  





















4a 2-CH3 CH3 NA NA 
4b 2-CH3 C2H5 NA NA 
4c 2-CH3 n-C4H9 1030.0±59.9 49.4±4.5 
4d 2,6-(CH3)2 n-C4H9 1258.0±4.8 57.5±2.1 
4e 2,4-(CH3)2 n-C4H9 1104.0±62.3 59.0±7.8 
4f 2-CF3 n-C4H9 467.093.8 20.43.6 
4g 2-C2H5 n-C4H9 73.515.9 12.71.4 
4h 2-I n-C4H9 429.097.3 20.31.1 
4i 2,4-Cl2 n-C4H9 NA NA 
4j 2,4-Br2 n-C4H9 NA NA 
4k 2-CH3 n-C5H11 1165.6±58.3 59.8±2.8 
4l 2-CH3 n-C6H13 1225.0±75.0 75.7±3.1 













Lidocaine   831.755.6 37.8  3.7 
Ropivacaine   1001.186.1 58.42.7 
Bupivacaine   1218.029.3 94.03.5 
a 
Regnier Index - indicator of the anaesthesia depth during first 60 min after the compound 
application expressed as a sum of the threshold tactile stimuli needed to induce corneal reflex (13 
series, up to 100 stimuli per one series) [23] 
  














(mice, i. v.) 
ED50, mg/kg 
(mice, i. v.) 
Antiarrhythmic 
index  
(LD50 / ED50) 
4a 2-CH3 CH3 32.5 (26.0-40.0) > 16.3
a NA 
4b 2-CH3 C2H5 36.8 (26.0-50.0) > 18.4
a NA 
4c 2-CH3 n-C4H9 16.3 (14.0-19.0) 5.4 (4.0-7.5) 3.0 
4d 2,6-(CH3)2 n-C4H9 9.2 (6.7-12.7) > 4.6
a NA 
4e 2,4-(CH3)2 n-C4H9 60.0 (48.0-74.0) > 30.0
a NA 
4f 2-CF3 n-C4H9 35.5 (29.0-42.0) 5.8 (4.2-8.0) 6.1 
4g 2-C2H5 n-C4H9 30.0 (24.0-38.0) 7.1 (5.9-8.4) 4.2 
4h 2-I n-C4H9 41.0 (35.0-47.0) 7.3 (5.3-10.0) 5.6 
4i 2,4-Cl2 n-C4H9 32.5 (26.0-40.0) > 16.3
a NA 
4j 2,4-Br2 n-C4H9 239.0 (190.0-300.0) 69.0 (50.0-95.0) 3.5 
4k 2-CH3 n-C5H11 32.5 (28.0-38.0) 5.5 (4.0-7.5) 5.9 
4l 2-CH3 n-C6H13 35.5 (29.0-42.0) 5.6 (4.9-6.4) 6.3 
4m 2-CH3 PhCH2 35.5 (31.0-40.0) 10.9 (8.0-15.0) 3.3 
4n 2-CH3 
 
12.9(10.0-16.0) > 6.5a NA 
4o 2,4-(CH3)2 
 
65.0 (56.0-75.0) 8.9 (7.8-10.2) 7.3 
4p 2-Cl 
 
95.0 (76.0-119.0) 13.7 (10-19) 6.9 
Cyclomecaine 2,4,6-(CH3)3 
 
15.0 (12.0-17.0) 2.9 (2.2-3.0) 5.2 
Lidocaine   39.3 (34.2-44.5) 7.7 (5.9-9.4) 5.1 
Ropivacaine   14.1 (12.0-17.0) 3.7 (2.6-5.0) 3.8 
Bupivacaine   8.9 (7.5-10.6) 3.5 (3.1-4.0) 2.5 












































































                R1                  R2
4a         2-CH3              CH3 
4b         2-CH3             C2H5
4c         2-CH3           n-C4H9 
4d     2,6-(CH3)2        n-C4H9
4e     2,4-(CH3)2        n-C4H9
4f         2-CF3            n-C4H9
4g        2-C2H5          n-C4H9
4h            2-I             n-C4H9
4i        2,4-Cl2           n-C4H9
4j        2,4-Br2           n-C4H9
4k         2-CH3          n-C5H11
4l          2-CH3          n-C6H13
4m        2-CH3         C6H5CH2
4n         2-CH3        cyclo-C6H11
4o      2,4-(CH3)2    cyclo-C6H11
4p          2-Cl          cyclo-C6H11
 
Scheme 1 
 
 
